Recently Expired Drugs

1. Drug name - AMITIZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8097653 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation
Nov, 2022

(25 days ago)

US8389542 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation
Nov, 2022

(25 days ago)

US6982283 SUCAMPO PHARMA LLC Method for treating drug-induced constipation
Dec, 2022

(5 days ago)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MCG CAPSULE;ORAL Prescription
24MCG CAPSULE;ORAL Prescription

2. Drug name - AMLODIPINE BESYLATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6828339 SYNTHON PHARMS Amlodipine salt forms and processes for preparing them
Nov, 2022

(19 days ago)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 27 September, 2007

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
EQ 5MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
EQ 10MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

3. Drug name - BANZEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(25 days ago)

Drugs and Companies using RUFINAMIDE ingredient

Market Authorisation Date: 03 March, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
40MG/ML SUSPENSION;ORAL Prescription

4. Drug name - HETLIOZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(23 hours ago)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

5. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(23 hours ago)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

6. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384649 ACORDA Particulate compositions for pulmonary delivery
Nov, 2022

(19 days ago)

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

7. Drug name - NEURONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7256216

(Pediatric)

VIATRIS Liquid pharmaceutical compositions
Nov, 2022

(11 days ago)

Drugs and Companies using GABAPENTIN ingredient

Market Authorisation Date: 02 March, 2000

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
250MG/5ML SOLUTION;ORAL Prescription

8. Drug name - OCALIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7138390 INTERCEPT PHARMS INC Steroids as agonists for FXR
Nov, 2022

(23 days ago)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2023

Drugs and Companies using OBETICHOLIC ACID ingredient

Market Authorisation Date: 27 May, 2016

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

9. Drug name - PROMACTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(19 days ago)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 16, 2025
Pediatric Exclusivity (PED) Feb 26, 2022

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 20 November, 2008

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID TABLET;ORAL Prescription
EQ 25MG ACID TABLET;ORAL Prescription
EQ 50MG ACID TABLET;ORAL Prescription
EQ 75MG ACID TABLET;ORAL Prescription
EQ 100MG ACID TABLET;ORAL Discontinued

10. Drug name - PROMACTA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(19 days ago)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 16, 2025
Pediatric Exclusivity (PED) Feb 26, 2022

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 24 August, 2015

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID/PACKET FOR SUSPENSION;ORAL Prescription
EQ 25MG ACID/PACKET FOR SUSPENSION;ORAL Prescription

11. Drug name - SELZENTRY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(14 days ago)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 30, 2023
Pediatric Exclusivity (PED) Apr 30, 2024

Drugs and Companies using MARAVIROC ingredient

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
20MG/ML SOLUTION;ORAL Prescription

12. Drug name - SUMAVEL DOSEPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491524 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Nov, 2022

(18 days ago)

US8241244 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Nov, 2022

(18 days ago)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 15 July, 2009

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued

13. Drug name - VEREGEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10434059 ANI PHARMS Medicament for the treatment of viral skin and tumour diseases
Nov, 2022

(21 days ago)

Drugs and Companies using SINECATECHINS ingredient

Market Authorisation Date: 31 October, 2006

Treatment: Treatment of genital warts

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% OINTMENT;TOPICAL Prescription

14. Drug name - VIIBRYD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(4 days ago)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(4 days ago)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Dec, 2022

(4 days ago)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(4 days ago)

Exclusivity Exclusivity Expiration
M Jan 31, 2023
Pediatric Exclusivity (PED) Jul 31, 2023

Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 January, 2011

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

15. Drug name - XERESE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387 BAUSCH Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Nov, 2022

(26 days ago)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); Combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
5%;1% CREAM;TOPICAL Prescription

16. Drug name - XOFIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234 BAYER HLTHCARE Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Nov, 2022

(22 days ago)

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

Market Authorisation Date: 15 May, 2013

Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
162mCi/6ML (27mCi/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in